MELBOURNE, AUSTRALIA --(Marketwired - November 27, 2017) - Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc
Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary
treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced
that it will be presenting at the 10th annual LD Micro Main Event on Thursday, December 7th at 11:30 AM PST / 2:30 PM EST at the
Luxe Sunset Boulevard Hotel in Los Angeles, CA. The LD Micro Main Event is the largest independent conference for small/microcap
companies and will feature 240 presenting companies.
James Nathanielsz, Propanc Biopharma's Chief Executive Officer, will be presenting as well as meeting with investors to
discuss the Company' operations and future plans, focusing on anticipated near term milestones as the Company advances its lead
product, PRP, towards First-In-Human studies in 2018.
"I look forward to updating investors on our recent progress, including the completion of preclinical development for PRP,
obtaining Orphan Drug Designation from the FDA for PRP's treatment of pancreatic cancer with a second ODD request filed for
ovarian cancer pending, and its potential as a breakthrough product for many aggressive cancers," said James Nathanielsz, Propanc
Biopharma's Chief Executive Officer. "In addition, I will be updating investors regarding our capital structure, balance sheet
and plans for financing the clinical development of PRP, as well as the future expansion of our joint research program with our
partner universities."
PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and
chymotrypsinogen. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from
solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer.
According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health
states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by
2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated
combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's profile, please click on the following link: http://www.ldmicro.com/profile/PPCB
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following
link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request
form.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as
a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences
annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively
provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the
small and microcap universe. For those interested in attending, please contact David Scher at: david@ldmicro.com, or visit: www.ldmicro.com/events
for more information.
About Propanc Biopharma:
Propanc Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients
suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert
a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve
or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with
limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to
treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of
developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-Looking Statements:
All statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of
federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate," "intend,"
"continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or
assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to
change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our
ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products,
services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the
patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products,
our ability to implement our long range business plan for various applications of our technology, our ability to enter into
agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the
results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and
any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual
results to differ materially from those projected may be described from time to time in reports we file with the Securities and
Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update
any forward-looking statement contained herein, except as required by law.